Learn how Aureus Pharma streamlines critical research functions…
EVENT SCHEDULE
 American Chemical Society
August 17-21
 ICIC meeting
October 19-22
  See all events
  Register for free demonstration
REQUEST WEB DEMO
  Examine Aureus Pharma’s Knowledge Management System from your desk
Aureus Pharma appoints Jason Theodosiou as new CEO;
Past CEO André Michel appointed Chairman of the Supervisory Board

Paris, FRANCE, December 19, 2006 - Aureus Pharma announced today changes in Aureus's Executive and Supervisory Boards. Jason Theodosiou has been appointed Chief Executive Officer (CEO). Theodosiou will replace André Michel, founder of Aureus who has been appointed to Chairman of the Supervisory Board. These changes will become effective immediately.

"I am pleased and honored to become Aureus´ CEO" commented Theodosiou. "I would also like to express gratitude to André for both his vision in founding Aureus Pharma as well for his contributions during the past years. Aureus is today a leader in knowledge management solutions and we are looking forward to continue growing our organization, our market and serving our customers."

Mr. Theodosiou was previously Chief Operating Officer of Aureus. Prior to Aureus, he held various executive management positions at various companies including Elsevier MDL, Lion Bioscience, and EMAX/SciQuest.

André Michel, founder and CEO of the company since 2000, was previously Professor of Chemistry at Sherbrooke University (Canada) and Director of the Discovery Centers at Servier.




About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharmaceutical topics including ADME/Drug-Drug Interactions and the hERG Channel. The information contained in the Aureus Pharma system is of primary importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus Pharma helps researchers turn data into discovery visit www.aureus-pharma.com



Media Contact:

For Aureus Pharma:
Mary E. Donlan, Ph.D
Director of Marketing & Sales
+33 1 40 18 57 59/+33 6 76 19 51 77
mary.donlan@aureus-pharma.com

Back
ALL RIGHTS RESERVED BY AUREUS-PHARMA. COPYRIGHT 2004
LEGAL INFO PRIVACY NOTICE LICENSE AGREEMENT SITE MAP TRADEMARKS CUSTOMER LOGIN